Role of Tramadol in Premature Ejaculation: A Systematic Review and Meta-Analysis
Authors:
- Shengqiang QianSQShengqiang Qian
- Huawei LiuHLHuawei Liu
- Liangren LiuLLLiangren Liu
- Chunxiao PuCPChunxiao Pu
- Ping HanPHPing Han
- Qiang WeiQWQiang Wei
- 6 June 2013
- journal article
- review article
- Published by S. Karger AG in Urologia Internationalis
- Vol. 91 (2) , 197-205
Abstract
Objective: This systematic review was performed to evaluate the efficacy and safety of tramadol in patients with premature ejaculation (PE). Methods: A systematic search of PubMed®, Embase® and the Cochrane Library was performed to identify all randomized controlled trials (RCTs) that compared the effects of tramadol with placebo or no drug for patients with PE. The outcomes included post-therapeutic intravaginal ejaculation latency time (IELT), increases in IELT, satisfaction with sexual intercourse, control over ejaculation and side effects (SEs). The Cochrane Collaboration Review Manager software (RevMan 5.1.4) was used for statistical analysis. Results: A total of 5 trials, involving 715 patients, met the inclusion criteria. The synthesized data from these RCTs indicated that compared with the control, tramadol significantly increased IELT values post-therapeutically (SMD 3.51, 95% CI 2.14-4.88, p < 0.00001) and changes in IELT values were more pronounced in the tramadol group (SMD 2.87, 95% CI 2.63-3.10, p < 0.00001). Satisfaction with sexual intercourse and the ability to control ejaculation were both improved in patients in the tramadol group (p < 0.05). The incidence of SEs in the tramadol group were significantly higher than in the control group (RR 3.55, 95% CI 1.34-9.40, p = 0.01), however most SEs were mild or moderate and transient. Conclusions: Tramadol may be effective in PE treatment, especially when patients have failed therapies, like selective serotonin reuptake inhibitors. However, the possibility of drug addiction and SEs should still be considered before initial use or after chronic use of this agent. More high-quality (clear randomization sequences, allocation concealment and blinding introduction), long-term, RCTs with a large number of PE patients are expected.Keywords
This publication has 20 references indexed in Scilit:
- Evaluation of Tramadol on Demand Vs. Daily Paroxetine as a Long-Term Treatment of Lifelong Premature EjaculationThe Journal of Sexual Medicine, 2010
- Guidelines on Male Sexual Dysfunction: Erectile Dysfunction and Premature EjaculationEuropean Urology, 2010
- Tramadol for Premature EjaculationThe Journal of Sexual Medicine, 2009
- Impact of Premature Ejaculation: The Psychological, Quality of Life, and Sexual Relationship ConsequencesThe Journal of Sexual Medicine, 2008
- Premature Ejaculation: Current Medical Treatment and New Directions (CME)The Journal of Sexual Medicine, 2008
- Tramadol HCL has Promise in On-Demand Use to Treat Premature EjaculationThe Journal of Sexual Medicine, 2008
- A review of the current status of topical treatments for premature ejaculationBJU International, 2007
- A Comparison of the Abuse Liability of Tramadol, NSAIDs, and Hydrocodone in Patients with Chronic PainJournal of Pain and Symptom Management, 2006
- AUA GUIDELINE ON THE PHARMACOLOGIC MANAGEMENT OF PREMATURE EJACULATIONJournal of Urology, 2004
- Relevance of methodological design for the interpretation of efficacy of drug treatment of premature ejaculation: a systematic review and meta-analysisInternational Journal Of Impotence Research, 2004